Investor Presentaiton

Investor presentation First three months of 2017 Strong market leadership of Victoza ® in Latin America GLP-1 value in bDKK Latin America GLP-1 market VictozaⓇ dulaglutide - other exenatide 0.5 CAGR value¹: 14% 0.4 0.3 0.2 0.1 0.0 Feb 2012 1 CAGR for 5-year period Source: IMS Monthly MAT February, 2017 value figures (DKK) changing diabetes Slide 60 VictozaⓇ value market share in Latin America Share of total GLP-1 value diabetes care market share VictozaⓇ dulaglutide other exenatide market 100% 7% 87% 6% 80% 5% 60% 4% 3% 40% 2% 20% 1% 0% 0% Feb Feb 2017 2012 10% 2% 1% Feb 2017 Source: IMS Monthly MAT February, 2017 value figures (DKK) novo nordisk

View entire presentation